Evoke Pharma's Gimoti On Way To US FDA On 'Mixed' Data
Executive Summary
Evoke Pharma's share price fluctuated wildly after it announced new data for its gastroparesis therapy that were not quite as positive as they first appeared. A US filing is scheduled.
You may also be interested in...
Keeping Track: Mylan Wins First US FDA Approval For Neulasta Biosimilar, But Lands A CRL For Insulin Glargine; Genentech Nabs Broad Full Approval For Venclexta, PV Indication For Rituxan
The latest drug development news and highlights from our US FDA Performance Tracker.
Aptinyx To Forge Ahead With Pivotal PTSD Study
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Approval Beckons For Orchard’s Gene Therapy Libmeldy
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports